OBJECTIVES: To determine the value of peritoneal washing cytology (CY) in determining resectability of pancreatic cancer. SUMMARY BACKGROUND DATA: CY has been used widely in the diagnosis and staging of several cancers. However, its predictive value in identifying potentially resectable pancreatic cancer is undetermined. METHODS: Peritoneal washing samples were collected from 233 patients with pancreatic cancer between June 1991 and August 2006. A total of 157 patients had resectable and 76 had unresectable lesions. Correlations between CY status and clinicopathologic parameters with overall survival rates were analyzed. RESULTS: Malignant cells were identified in samples from 21 patients (13.4%) with resectable tumors and 27 patients (35.5%) with unresectable tumors. CY+ was more frequent in large tumors (> or =2 cm) than small tumors (<2 cm; P = 0.034). CY status did not correlate with any other clinicopathologic parameter. The overall survival of CY+ patients was worse than that of CY- patients (P = 0.047). Median survival following resection was 13.6 months for CY+ patients and 13.5 months for CY- patients. Among the patients who had unresectable lesions, median survival time was 5.9 months for CY+ and 6.1 months for CY- patients. However, among CY+ patients, those who underwent resection lived longer than those who did not (P = 0.019). CONCLUSIONS: Cytologic status has little predictive value for survival, and patients whose pancreatic cancer would otherwise be considered resectable should not be denied curative resection solely because they are CY+.
OBJECTIVES: To determine the value of peritoneal washing cytology (CY) in determining resectability of pancreatic cancer. SUMMARY BACKGROUND DATA: CY has been used widely in the diagnosis and staging of several cancers. However, its predictive value in identifying potentially resectable pancreatic cancer is undetermined. METHODS: Peritoneal washing samples were collected from 233 patients with pancreatic cancer between June 1991 and August 2006. A total of 157 patients had resectable and 76 had unresectable lesions. Correlations between CY status and clinicopathologic parameters with overall survival rates were analyzed. RESULTS: Malignant cells were identified in samples from 21 patients (13.4%) with resectable tumors and 27 patients (35.5%) with unresectable tumors. CY+ was more frequent in large tumors (> or =2 cm) than small tumors (<2 cm; P = 0.034). CY status did not correlate with any other clinicopathologic parameter. The overall survival of CY+ patients was worse than that of CY- patients (P = 0.047). Median survival following resection was 13.6 months for CY+ patients and 13.5 months for CY- patients. Among the patients who had unresectable lesions, median survival time was 5.9 months for CY+ and 6.1 months for CY- patients. However, among CY+ patients, those who underwent resection lived longer than those who did not (P = 0.019). CONCLUSIONS: Cytologic status has little predictive value for survival, and patients whose pancreatic cancer would otherwise be considered resectable should not be denied curative resection solely because they are CY+.
Authors: E Bando; Y Yonemura; Y Takeshita; K Taniguchi; T Yasui; Y Yoshimitsu; S Fushida; T Fujimura; G Nishimura; K Miwa Journal: Am J Surg Date: 1999-09 Impact factor: 2.565
Authors: Ji Hyang Kim; Jin Young Lee; Kyu Taek Lee; Jong Kyoon Lee; Kwang Hyuck Lee; Kee-Taek Jang; Jin Seok Heo; Seong Ho Choi; Jong Chul Rhee Journal: Tumour Biol Date: 2010-06-23